<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2020-4-158-166</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-4164</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Фактор роста плаценты модулирует ответ активированных in vitro T-клеток</article-title><trans-title-group xml:lang="en"><trans-title>Placental growth factor exerts modulatory effects on in vitro activated T cells</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сметаненко</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Smetanenko</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"><p>14, Yadrintsevskaya Str., Novosibirsk, 630099, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3169-8643</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Леплина</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Leplina</surname><given-names>O. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"><p>14, Yadrintsevskaya Str., Novosibirsk, 630099, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2366-1667</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тихонова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tikhonova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"><p>14, Yadrintsevskaya Str., Novosibirsk, 630099, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пасман</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Pasman</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, зав. кафедрой акушерства и гинекологии, Институт медициныи психологии</p><p>Россия, 630090, г. Новосибирск, ул. Пирогова, 2</p></bio><bio xml:lang="en"><p>2, Pirogova Str., Novosibirsk, 630090, Russian Federation</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6895-938X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Останин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostanin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"><p>14, Yadrintsevskaya Str., Novosibirsk, 630099, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2346-6279</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черных</surname><given-names>Е. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernykh</surname><given-names>E. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, член-корр. РАН, зав. лабораторией клеточной иммунотерапии, </p><p>Россия, 630099, г. Новосибирск, ул. Ядринцевская, 14 </p></bio><bio xml:lang="en"><p>14, Yadrintsevskaya Str., Novosibirsk, 630099, Russian Federation</p></bio><email xlink:type="simple">ct_lab@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт фундаментальной и клинической иммунологии (НИИФКИ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Fundamental and Clinical Immunology (RIFCI)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Новосибирский национальный исследовательский государственный университет (ННИГУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Medicine and Psychology, Novosibirsk National Research State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>19</volume><issue>4</issue><fpage>158</fpage><lpage>166</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сметаненко Е.А., Леплина О.Ю., Тихонова М.А., Пасман Н.М., Останин А.А., Черных Е.Р., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Сметаненко Е.А., Леплина О.Ю., Тихонова М.А., Пасман Н.М., Останин А.А., Черных Е.Р.</copyright-holder><copyright-holder xml:lang="en">Smetanenko E.A., Leplina O.Y., Tikhonova M.A., Pasman N.M., Ostanin A.A., Chernykh E.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/4164">https://bulletin.ssmu.ru/jour/article/view/4164</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Недавние исследования выявили иммуносупрессивные свойства фактора роста эндотелия сосудов (VEGF-A) и его ключевую роль в опухоль-индуцированной иммуносупрессии. Плацентарный фактор роста (PlGF) является еще одним представителем семейства VEGF, резкое возрастание которого ассоциировано с эффективной иммунной адаптацией при успешной беременности, тогда как низкие  концентрации PlGF являются предиктором гестационных осложнений на фоне активации  иммунной системы. Ранее нами показано, что активированные Т-клетки экспрессируют рецепторы VEGF 1-го типа (VEGFR-1) и PlGF через связывание с VEGFR-1 ингибирует пролиферацию Т-клеток.</p></sec><sec><title>Цель</title><p>Цель. Дальнейшее изучение влияния PlGF на T-клеточный ответ in vitro.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Мононуклеарные клетки (МНК) периферической крови здоровых доноров стимулировали моноклональными анти-CD3-антителами (a-CD3) в отсутствие и присутствии рекомбинантного PlGF и оценивали продукцию интерлейкина-10 (IL-10), уровень апоптоза и экспрессию ингибиторных рецепторов (PD-1, CTLA-4, Tim-3) в  субпопуляциях CD4+ и CD8+ T-клеток. </p></sec><sec><title>Результаты</title><p>Результаты. Активация МНК a-CD3 в присутствии PlGF приводила к возрастанию относительного содержания CD4+ и CD8+ T-клеток, продуцирующих IL-10. Кроме того, PlGF усиливал апоптоз активированных CD8+ T-лимфоцитов, не влияя значимо на уровень программированной клеточной гибели CD4+ Т-клеток. Характерно, что активация Т-клеток a-CD3 в присутствии PlGF сопровождалась возрастанием PD-1  экспрессирующих клеток в субпопуляции CD8+ Т-клеток и Tim-3-экспрессирующих клеток среди CD4+ и CD8+ Т-клеток, а также повышением уровня экспрессии PD-1 и Tim-3 на Т-клетках.</p></sec><sec><title>Заключение</title><p>Заключение. PlGF способен ингибировать Т-клеточный ответ посредством усиления продукции IL-10 и активационно-индуцированного апоптоза CD8+ Т-клеток, а также экспрессии ингибиторных рецепторов. Учитывая повышенный уровень PlGF при физиологической беременности и его снижение при гестационных осложнениях,  полученные данные позволяют предполагать, что ингибиторный эффект PlGF на Т-клеточный ответ может являться еще одним механизмом, обеспечивающим защиту плода  от иммунной системы матери.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Recent studies demonstrated immunosuppressive properties of vascular endothelial growth factor (VEGF-A) and identified VEGF-A as a key mediator of tumor-induced immunosuppression. Placental growth factor (PlGF) is another member of VEGF family in which dramatic elevation is associated with effective immune adaptation in successful pregnancy, whereas low concentrations are related to pregnancy complications resulting from the activation of immune system. Previously, we have shown that activated T cells express VEGF receptor type 1 (VEGFR-1), and PlGF inhibits T cell proliferation in VEGFR-1–dependent manner.</p><p>The aim of the present study was to further characterize PlGF effects on T cell responses in vitro.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Peripheral blood mononuclear cells (PBMC) from healthy donors were stimulated with anti-CD3 monoclonal antibodies (a-CD3) in the absence or presence of PlGF and assessed for IL-10 production, programmed cell death and the expression of inhibitory receptors (PD-1, CTLA-4, Tim-3) in CD4+ and CD8+ T cell subsets.</p></sec><sec><title>Results</title><p>Results. The addition of PlGF to PBMC cultures activated with a-CD3 resulted in increased percentages of IL- 10-producing CD4+ and CD8+ T cells. Besides, PlGF promoted CD8+ T cells apoptosis while did not affect programmed cell death within CD4+ T cells. Notable, T cell activation with a-CD3 in the presence of PlGF was accompanied by the enhancement of PD-1-expressing cells in CD8+ T cell subset and Tim-3-expressing cells in both CD4+ and CD8+ T cells, and by the increased expression of PD-1 and Tim-3 on T cells.</p></sec><sec><title>Conclusion</title><p>Conclusion. Our in vitro findings indicate that PlGF can inhibit T cell responses due to the increasing interleukin-10 (IL-10) production, promoting CD8+ T cell apoptosis and enhancing the expression of PD-1 and Tim-3 inhibitory receptors. Given the elevated levels of PlGF in successful pregnancy and its decrease in gestation complications, the obtained data also suggest that PlGF-mediated suppression may be implicated into the governing immune evasion in pregnancy. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>PlGF</kwd><kwd>Т-клетки</kwd><kwd>апоптоз</kwd><kwd>IL-10</kwd><kwd>ингибиторные рецепторы</kwd><kwd>PD-1</kwd><kwd>CTLA-4</kwd><kwd>Tim-3</kwd></kwd-group><kwd-group xml:lang="en"><kwd>PlGF</kwd><kwd>T cells</kwd><kwd>apoptosis</kwd><kwd>IL-10</kwd><kwd>inhibitory receptors</kwd><kwd>PD-1</kwd><kwd>CTLA-4</kwd><kwd>Tim-3</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке РФФИ и Правительства Новосибирской области (проект № 18-44-540005р-а).</funding-statement><funding-statement xml:lang="en">The study was supported by the Russian Foundation for Basic Research and the government of Novosibirsk region (Project No. 18-44-540005r-a).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Stuttfeld E., Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009; 61 (9): 915–922. DOI: 10.1002/iub.234.</mixed-citation><mixed-citation xml:lang="en">Stuttfeld E., Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009; 61 (9): 915–922. DOI: 10.1002/iub.234.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">De Falco S. The discovery of placenta growth factor and its biological activity. Exp. Mol. Med. 2012; 44 (1): 1–9. DOI: 10.3858/emm.2012.44.1.025.</mixed-citation><mixed-citation xml:lang="en">De Falco S. The discovery of placenta growth factor and its biological activity. Exp. Mol. Med. 2012; 44 (1): 1–9. DOI: 10.3858/emm.2012.44.1.025.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dewerchin M., Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb. Perspect Med. 2012; 2 (8): a011056. DOI: 10.1101/cshperspect.a011056.</mixed-citation><mixed-citation xml:lang="en">Dewerchin M., Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb. Perspect Med. 2012; 2 (8): a011056. DOI: 10.1101/cshperspect.a011056.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Voron T., Marcheteau E., Pernot S., Colussi O., Tartour E., Taieb J., Terme M. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014; 4: 70. DOI: 10.3389/fonc.2014.00070.</mixed-citation><mixed-citation xml:lang="en">Voron T., Marcheteau E., Pernot S., Colussi O., Tartour E., Taieb J., Terme M. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014; 4: 70. DOI: 10.3389/fonc.2014.00070.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lapeyre-Prost A., Terme M., Pernot S., Pointet A.L., Voron T., Tartour E., Taieb J. Immunomodulatory activity of VEGF in cancer. Int. Rev. Cell Mol. Biol. 2017; 330: 295–342. DOI: 10.1016/bs.ircmb.2016.09.007.</mixed-citation><mixed-citation xml:lang="en">Lapeyre-Prost A., Terme M., Pernot S., Pointet A.L., Voron T., Tartour E., Taieb J. Immunomodulatory activity of VEGF in cancer. Int. Rev. Cell Mol. Biol. 2017; 330: 295–342. DOI: 10.1016/bs.ircmb.2016.09.007.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Y.L., Liang Y.C., Chiang B.L. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J. Leukoc. Biol. 2007; 82 (6): 1473–1480. DOI: 10.1189/jlb.0307164.</mixed-citation><mixed-citation xml:lang="en">Lin Y.L., Liang Y.C., Chiang B.L. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J. Leukoc. Biol. 2007; 82 (6): 1473–1480. DOI: 10.1189/jlb.0307164.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ziogas A., Gavalas N., Tsiatas M., Tsitsilonis O., Politi E., Terpos E., Rodolakis A., Vlahos G., Thomakos N., Haidopoulos D., Antsaklis A., Dimopoulos M., Bamias A. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int. J. Cancer. 2012; 130 (4): 857–864. DOI: 10.1002/ijc.26094.</mixed-citation><mixed-citation xml:lang="en">Ziogas A., Gavalas N., Tsiatas M., Tsitsilonis O., Politi E., Terpos E., Rodolakis A., Vlahos G., Thomakos N., Haidopoulos D., Antsaklis A., Dimopoulos M., Bamias A. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int. J. Cancer. 2012; 130 (4): 857–864. DOI: 10.1002/ijc.26094.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Albonici L., Giganti M., Modesti A., Manzari V., Bei R. Multifaceted role of the placental growth factor (PlGF) in the antitumor immune response and cancer progression. Int. J. Mol. Sci. 2019; 20 (12): е2970. DOI: 10.3390/ijms20122970.</mixed-citation><mixed-citation xml:lang="en">Albonici L., Giganti M., Modesti A., Manzari V., Bei R. Multifaceted role of the placental growth factor (PlGF) in the antitumor immune response and cancer progression. Int. J. Mol. Sci. 2019; 20 (12): е2970. DOI: 10.3390/ijms20122970.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Meng F.-J., Xiao S.-X., Zhang Y., Wang W., Wang B., Fan X.-Y. Prognostic significance of placenta growth factor expression in patients with multiple cancers: a meta-analysis. Int. J. Clin. Exp. Med. 2015; 8 (8): 12726–12735.</mixed-citation><mixed-citation xml:lang="en">Meng F.-J., Xiao S.-X., Zhang Y., Wang W., Wang B., Fan X.-Y. Prognostic significance of placenta growth factor expression in patients with multiple cancers: a meta-analysis. Int. J. Clin. Exp. Med. 2015; 8 (8): 12726–12735.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lecarpentier É., Vieillefosse S., Haddad B., Fournier T., Leguy M., Guibourdenche J., Tsatsaris V. Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia. Ann. Biol. Clin. (Paris). 2016; 74 (3): 259–267. DOI: 10.1684/abc.2016.1158.</mixed-citation><mixed-citation xml:lang="en">Lecarpentier É., Vieillefosse S., Haddad B., Fournier T., Leguy M., Guibourdenche J., Tsatsaris V. Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia. Ann. Biol. Clin. (Paris). 2016; 74 (3): 259–267. DOI: 10.1684/abc.2016.1158.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Morelli S., Mandal M., Goldsmith L.T., Kashani B.N., Ponzio N.M. The maternal immune system during pregnancy and its influence on fetal development. Research and Reports in Biology. 2015; 6: 171–189. DOI: 10.2147/RRB.S80652.</mixed-citation><mixed-citation xml:lang="en">Morelli S., Mandal M., Goldsmith L.T., Kashani B.N., Ponzio N.M. The maternal immune system during pregnancy and its influence on fetal development. Research and Reports in Biology. 2015; 6: 171–189. DOI: 10.2147/RRB.S80652.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Slutsky R., Romero R., Xu Y., Galaz J., Miller D., Done B., Tarca A.L., Gregor S., Hassan S.S., Leng Y., Gomez-Lopez N. Exhausted and senescent T cells at the maternal-fetal interface in preterm and term labor. J. Immunol. Res. 2019: 3128010. DOI: 10.1155/2019/3128010.</mixed-citation><mixed-citation xml:lang="en">Slutsky R., Romero R., Xu Y., Galaz J., Miller D., Done B., Tarca A.L., Gregor S., Hassan S.S., Leng Y., Gomez-Lopez N. Exhausted and senescent T cells at the maternal-fetal interface in preterm and term labor. J. Immunol. Res. 2019: 3128010. DOI: 10.1155/2019/3128010.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Y., Wang S., Lin Y., Li D., Du M. Tim-3 and PD-1 regulate CD8+ T cell function to maintain early pregnancy in mice. J. Reprod. Dev. 2017; 63 (3): 289–294. DOI: 10.1262/jrd.2016-177.</mixed-citation><mixed-citation xml:lang="en">Xu Y., Wang S., Lin Y., Li D., Du M. Tim-3 and PD-1 regulate CD8+ T cell function to maintain early pregnancy in mice. J. Reprod. Dev. 2017; 63 (3): 289–294. DOI: 10.1262/jrd.2016-177.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Черных Е.Р., Леплина О.Ю., Тихонова М.А., Баторов Е.В., Останин А.А. Сигналинг через рецептор к фактору роста эндотелия сосудов 1-го типа как новый механизм подавления Т-клеток при опухолевом неоангиогенезе. Медицинская иммунология. 2019; 21 (4): 653–660. DOI: 10.15789/1563-0625-2019-4-653-660.</mixed-citation><mixed-citation xml:lang="en">Черных Е.Р., Леплина О.Ю., Тихонова М.А., Баторов Е.В., Останин А.А. Сигналинг через рецептор к фактору роста эндотелия сосудов 1-го типа как новый механизм подавления Т-клеток при опухолевом неоангиогенезе. Медицинская иммунология. 2019; 21 (4): 653–660. DOI: 10.15789/1563-0625-2019-4-653-660.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bottomley M., Webb N., Watson C., Holt L., Bukhari M., Denton J., Freemont A., Brenchley P. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin. Exp. Immunol. 2000; 119 (1): 182–188. DOI: 10.1046/j.1365-2249.2000.01097.x.</mixed-citation><mixed-citation xml:lang="en">Bottomley M., Webb N., Watson C., Holt L., Bukhari M., Denton J., Freemont A., Brenchley P. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin. Exp. Immunol. 2000; 119 (1): 182–188. DOI: 10.1046/j.1365-2249.2000.01097.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dikov M., Ohm J., Ray N., Tchekneva E.E., Burlison J., Moghanaki D., Nadaf S., Carbone D.P. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 2005; 174 (1): 215–222. DOI: 10.4049/jimmunol.174.1.215.</mixed-citation><mixed-citation xml:lang="en">Dikov M., Ohm J., Ray N., Tchekneva E.E., Burlison J., Moghanaki D., Nadaf S., Carbone D.P. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 2005; 174 (1): 215–222. DOI: 10.4049/jimmunol.174.1.215.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011; 437 (2): 169– 183. DOI: 10.1042/BJ20110301.</mixed-citation><mixed-citation xml:lang="en">Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011; 437 (2): 169– 183. DOI: 10.1042/BJ20110301.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Oh H., Yu C.R., Golestaneh N., Amadi-Obi A., Lee Y.S., Eseonu A., Mahdi R.M., Egwuagu C.E. STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J. Biol. Chem. 2011; 286 (35): 30888–30897. DOI: 10.1074/jbc.M111.253500.</mixed-citation><mixed-citation xml:lang="en">Oh H., Yu C.R., Golestaneh N., Amadi-Obi A., Lee Y.S., Eseonu A., Mahdi R.M., Egwuagu C.E. STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J. Biol. Chem. 2011; 286 (35): 30888–30897. DOI: 10.1074/jbc.M111.253500.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Shin J.Y., Yoon I.H., Kim J.S., Kim B., Park C.G. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell Immunol. 2009; 256 (1–2): 72–78. DOI: 10.1016/j.cellimm.2009.01.006.</mixed-citation><mixed-citation xml:lang="en">Shin J.Y., Yoon I.H., Kim J.S., Kim B., Park C.G. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell Immunol. 2009; 256 (1–2): 72–78. DOI: 10.1016/j.cellimm.2009.01.006.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Mobini M., Mortazavi M., Nadi S., Zare-Bidaki M., Pourtalebi S., Arababadi M.K. Significant roles played by interleukin-10 in outcome of pregnancy. Iran J. Basic Med. Sci. 2016; 19 (2): 119–124.</mixed-citation><mixed-citation xml:lang="en">Mobini M., Mortazavi M., Nadi S., Zare-Bidaki M., Pourtalebi S., Arababadi M.K. Significant roles played by interleukin-10 in outcome of pregnancy. Iran J. Basic Med. Sci. 2016; 19 (2): 119–124.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sabat R., Grütz G., Warszawska K., Kirsch S., Witte E., Wolk K., Geginat J. Biology of interleukin-10. Cytokine</mixed-citation><mixed-citation xml:lang="en">Sabat R., Grütz G., Warszawska K., Kirsch S., Witte E., Wolk K., Geginat J. Biology of interleukin-10. Cytokine</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Growth Factor Rev. 2010; 21 (5): 331–344. DOI: 10.1016/j.cytogfr.2010.09.002.</mixed-citation><mixed-citation xml:lang="en">Growth Factor Rev. 2010; 21 (5): 331–344. DOI: 10.1016/j.cytogfr.2010.09.002.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Jankovic D., Kugler D., Sher A. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal. Immunol. 2010; 3 (3): 239–246. DOI: 10.1038/mi.2010.8.</mixed-citation><mixed-citation xml:lang="en">Jankovic D., Kugler D., Sher A. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal. Immunol. 2010; 3 (3): 239–246. DOI: 10.1038/mi.2010.8.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Emmerich J., Mumm J.B., Chan I.H., LaFace D., Truong H., McClanahan T., Gorman D.M., Oft M. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Research. 2012; 72 (14): 3570–3581. DOI: 10.1158/0008-5472.CAN-12-0721.</mixed-citation><mixed-citation xml:lang="en">Emmerich J., Mumm J.B., Chan I.H., LaFace D., Truong H., McClanahan T., Gorman D.M., Oft M. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Research. 2012; 72 (14): 3570–3581. DOI: 10.1158/0008-5472.CAN-12-0721.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Smith L.K., Boukhaled G.M., Condotta S.A., Mazouz S., Guthmiller J.J., Vijay R., Butler N.S., Bruneau J., Shoukry N.H., Krawczyk C.M, Richer M.J. Interleukin-10 directly inhibits CD8+ T cell function by enhancing N- glycan branching to decrease antigen sensitivity. Immunity. 2018; 48 (2): 299-312: e5. DOI: 10.1016/j.immuni.2018.01.006.</mixed-citation><mixed-citation xml:lang="en">Smith L.K., Boukhaled G.M., Condotta S.A., Mazouz S., Guthmiller J.J., Vijay R., Butler N.S., Bruneau J., Shoukry N.H., Krawczyk C.M, Richer M.J. Interleukin-10 directly inhibits CD8+ T cell function by enhancing N- glycan branching to decrease antigen sensitivity. Immunity. 2018; 48 (2): 299-312: e5. DOI: 10.1016/j.immuni.2018.01.006.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hou H., Cheng S., Chung K., Wei S., Tsao P., Lu H., Wang H., Yu C. PlGF mediates neutrophil elastase-induced airway epithelial cell apoptosis and emphysema. Respir. Res. 2014; 15 (1): 106. DOI: 10.1186/s12931-014-0106-1.</mixed-citation><mixed-citation xml:lang="en">Hou H., Cheng S., Chung K., Wei S., Tsao P., Lu H., Wang H., Yu C. PlGF mediates neutrophil elastase-induced airway epithelial cell apoptosis and emphysema. Respir. Res. 2014; 15 (1): 106. DOI: 10.1186/s12931-014-0106-1.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chiu Y.M., Tsai C.L., Kao J.T., Hsieh C.T., Shieh D.C., Lee Y.J., Tsay G.J., Cheng K.S., Wu Y.Y. PD-1 and PD-L1</mixed-citation><mixed-citation xml:lang="en">Chiu Y.M., Tsai C.L., Kao J.T., Hsieh C.T., Shieh D.C., Lee Y.J., Tsay G.J., Cheng K.S., Wu Y.Y. PD-1 and PD-L1</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">up-regulation promotes T-cell apoptosis in gastric adenocarcinoma. Anticancer Res. 2018; 38 (4): 2069–2078. DOI: 10.21873/anticanres.12446.</mixed-citation><mixed-citation xml:lang="en">up-regulation promotes T-cell apoptosis in gastric adenocarcinoma. Anticancer Res. 2018; 38 (4): 2069–2078. DOI: 10.21873/anticanres.12446.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Meggyes M., Miko E., Szigeti B., Farkas N., Szereday L. The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface. BMC Pregnancy Childbirth. 2019; 19 (1): 74. DOI: 10.1186/s12884-019-2218-6.</mixed-citation><mixed-citation xml:lang="en">Meggyes M., Miko E., Szigeti B., Farkas N., Szereday L. The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface. BMC Pregnancy Childbirth. 2019; 19 (1): 74. DOI: 10.1186/s12884-019-2218-6.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Shi F., Shi M., Zeng Z., Qi R., Liu Z., Zhang J., Yang Y., Tien P., Wang F.S. PD-1 and PD-L1 up-regulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer. 2011; 128 (4): 887–896. DOI: 10.1002/ijc.25397.</mixed-citation><mixed-citation xml:lang="en">Shi F., Shi M., Zeng Z., Qi R., Liu Z., Zhang J., Yang Y., Tien P., Wang F.S. PD-1 and PD-L1 up-regulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer. 2011; 128 (4): 887–896. DOI: 10.1002/ijc.25397.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee H., Kane L.P. Immune regulation by Tim-3.F1000Res. 2018; 7: 316. DOI: 10.12688/f1000research.13446.1.</mixed-citation><mixed-citation xml:lang="en">Banerjee H., Kane L.P. Immune regulation by Tim-3.F1000Res. 2018; 7: 316. DOI: 10.12688/f1000research.13446.1.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Voron T., Colussi O., Marcheteau E., Pernot S., Nizard M., Pointet A., Latreche S., Bergaya S., Benhamouda N., Tanchot C., Stockmann C., Combe P., Berger A., Zinzindohoue F., Yagita H., Tartour E., Taieb J., Terme M. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 2015; 212 (2): 139–148. DOI: 10.1084/jem.20140559.</mixed-citation><mixed-citation xml:lang="en">Voron T., Colussi O., Marcheteau E., Pernot S., Nizard M., Pointet A., Latreche S., Bergaya S., Benhamouda N., Tanchot C., Stockmann C., Combe P., Berger A., Zinzindohoue F., Yagita H., Tartour E., Taieb J., Terme M. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 2015; 212 (2): 139–148. DOI: 10.1084/jem.20140559.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J. Leukoc. Biol. 2013; 94 (2): 247–257. DOI: 10.1189/jlb.1112603.</mixed-citation><mixed-citation xml:lang="en">Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J. Leukoc. Biol. 2013; 94 (2): 247–257. DOI: 10.1189/jlb.1112603.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Geldenhuys J., Rossouw T., Lombaard H., Ehlers M., Kock M. Disruption in the regulation of immune responses in the placental subtype of preeclampsia. Front Immunol. 2018; 9: 1659. DOI: 10.3389/fimmu.2018.01659.</mixed-citation><mixed-citation xml:lang="en">Geldenhuys J., Rossouw T., Lombaard H., Ehlers M., Kock M. Disruption in the regulation of immune responses in the placental subtype of preeclampsia. Front Immunol. 2018; 9: 1659. DOI: 10.3389/fimmu.2018.01659.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
